Clinical Trials Group

Belkins
CTG (Clinical Trials Group) is a private contract research organization (CRO) experienced and specialized in conducting all phases (I-IV) clinical trials in various therapeutic areas. For over 10 years, many sponsors have been benefiting from CTG's global and local scientific, regulatory and information management expertise achieving timely and high-quality clinical trials data. With an experienced and reliable team on board, CTG is a confirmed trusted partner in clinical research which is enforced by high working standards of Quality Control (QC) and Quality Assurance (QA).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SMALL TACTICS TO COUNTER BIG PHARMA’S INFLUENCE ON MEDICATION OVERLOAD

STAT | January 28, 2020

news image

Money talks in Washington, D.C., and no sector of the economy speaks more loudly than the pharmaceutical and biotech industry. Its flow of cash has fostered an epidemic of medication overload. Over the past five years, pharma has spent about $1.2 billion lobbying federal lawmakers, far more than any other industry. The industry has massive influence over public policy, much of it devoted in recent months to hindering legislative efforts to lower drug prices. In addition to keeping prices high, t...

Read More

J&J LAUNCHES ‘MULTI-PRONGED’ CORONAVIRUS RESPONSE

PharmaTimes | January 30, 2020

news image

The company has initiated efforts to broadly collaborate with others in order to screen a library of antiviral therapies, hoping to identify compounds with antiviral activity against the virus – which is also known as 2019-nCoV or Wuhan coronavirus. Using its AdVac and PER.C6 technologies - the same technologies that were used in the development and manufacturing of Janssen's investigational Ebola vaccine - J&J has revealed plans to try and rapidly upscale production of the optimal...

Read More

PHARMACY MARKET

EIRION THERAPEUTICS ANNOUNCES STRATEGIC AGREEMENT FOR HTL BIOTECHNOLOGY TO BECOME EIRION'S EXCLUSIVE BOTULINUM API MANUFACTURER

Eirion Therapeutics, Inc. | September 09, 2021

news image

Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and other biopolymers, will become Eirion's exclusive botulinum active pharmaceutical ingredient (API) manufacturer. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and prima...

Read More

CVS HEAD OF SPECIALTY PHARMACY SEES FUTURE OF HEALTHCARE AT HOME AFTER COVID-19

Medcity news | May 26, 2020

news image

Mail-order prescriptions are nothing new, but pharmacists have turned to a number of other tools to help patients access their prescriptions during the Covid-19 pandemic. The head of CVS Health’s specialty pharmacy strategy, Prem Shah, said he expects to see more patients continue receive healthcare at home after the pandemic ends. Though CVS Health had been building up its arsenal of digital tools before the Covid-19 pandemic, stay-at-home orders forced the pharmacy giant to lean mo...

Read More

STAT | January 28, 2020

news image

SMALL TACTICS TO COUNTER BIG PHARMA’S INFLUENCE ON MEDICATION OVERLOAD

Money talks in Washington, D.C., and no sector of the economy speaks more loudly than the pharmaceutical and biotech industry. Its flow of cash has fostered an epidemic of medication overload. Over the past five years, pharma has spent about $1.2 billion lobbying federal lawmakers, far more than any other industry. The industry has massive influence over public policy, much of it devoted in recent months to hindering legislative efforts to lower drug prices. In addition to keeping prices high, t...

Read More

PharmaTimes | January 30, 2020

news image

J&J LAUNCHES ‘MULTI-PRONGED’ CORONAVIRUS RESPONSE

The company has initiated efforts to broadly collaborate with others in order to screen a library of antiviral therapies, hoping to identify compounds with antiviral activity against the virus – which is also known as 2019-nCoV or Wuhan coronavirus. Using its AdVac and PER.C6 technologies - the same technologies that were used in the development and manufacturing of Janssen's investigational Ebola vaccine - J&J has revealed plans to try and rapidly upscale production of the optimal...

Read More

PHARMACY MARKET

Eirion Therapeutics, Inc. | September 09, 2021

news image

EIRION THERAPEUTICS ANNOUNCES STRATEGIC AGREEMENT FOR HTL BIOTECHNOLOGY TO BECOME EIRION'S EXCLUSIVE BOTULINUM API MANUFACTURER

Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and other biopolymers, will become Eirion's exclusive botulinum active pharmaceutical ingredient (API) manufacturer. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and prima...

Read More

Medcity news | May 26, 2020

news image

CVS HEAD OF SPECIALTY PHARMACY SEES FUTURE OF HEALTHCARE AT HOME AFTER COVID-19

Mail-order prescriptions are nothing new, but pharmacists have turned to a number of other tools to help patients access their prescriptions during the Covid-19 pandemic. The head of CVS Health’s specialty pharmacy strategy, Prem Shah, said he expects to see more patients continue receive healthcare at home after the pandemic ends. Though CVS Health had been building up its arsenal of digital tools before the Covid-19 pandemic, stay-at-home orders forced the pharmacy giant to lean mo...

Read More